Crohn's disease trials recruiting in Virginia
All Crohn's disease trials nationally
17
Recruiting in Virginia
10
Cities with sites
Cities in Virginia
Richmond 6Roanoke 5Lynchburg 4Charlottesville 3Chesapeake 2Williamsburg 2Fairfax 1Lansdowne Town Center 1Norfolk 1Suffolk 1
Recruiting trials in Virginia
- A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
- A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
- A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
- A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
- A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
- A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
- An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
- Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
- Ketogenic and Carnivore (Lion) Diets for Inflammatory Bowel Disease and Rheumatoid Arthritis
- Precise Infliximab Exposure and Pharmacodynamic Control
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission